Health & Fitness

According to FutureWise analysis the market for MRI-guided Neurosurgical Ablation in 2026 is US$ 0.47 billion, and is expected to reach US$ 1.23 billion by 2036 at a CAGR of 10.10%. MRI-guided neurosurgical ablation is a minimally invasive procedure that utilizes real-time imaging to accurately target and destroy abnormal brain tissue, like tumors or epileptic foci. This method improves surgical precision, spares healthy tissue, and shortens recovery compared to traditional surgery. The market is expanding due to the rising use of image-guided therapies, the increasing prevalence of neurological disorders, and advancements in thermal ablation technologies. MRI-guided neurosurgical ablation is an innovative and minimally invasive technique designed to treat a range of neurological conditions by accurately targeting and eliminating abnormal brain tissue. This method uses real-time magnetic resonance imaging (MRI) to guide the procedure, enhancing the precision of treatment. Through the ... Continue reading →

According to FutureWise analysis, the Mucopolysaccharidosis Market in 2026 is US$3.27 billion, and is expected to reach US$6.19 billion by 2036 at a CAGR of 6.59%. Mucopolysaccharidosis (MPS) refers to a group of rare metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes known as glycosaminoglycan. This disorder leads to an inability to break down certain sugars in the body, resulting in the accumulation of compounds such as heparan sulfate, keratan sulfate, and dermatan sulfate, which interfere with the normal functioning of body cells. Severe neurological symptoms, including Sanfilippo syndrome and Hunter syndrome, are among the primary manifestations of mucopolysaccharidosis. Key players in the pharmaceutical industry are actively researching and developing advanced therapies to manage these symptoms. The increasing number of candidates from these key players in the rare disease therapeutic sector is expected to boost the growth of the ... Continue reading →

According to FutureWise analysis the market for MRI-guided Radiation Therapy Systems in 2026 is US$ 0.76 billion, and is expected to reach US$ 2.65 billion by 2036 at a CAGR of 13.30%. MRI-guided radiation therapy systems combine real-time MRI with linear accelerators to deliver precise radiation doses to tumors. This continuous visualization enables real-time treatment adjustments, improving targeting accuracy and reducing exposure to healthy tissues. Key factors driving market growth include rising demand for adaptive radiotherapy, increasing cancer incidence, and advancements in image-guided oncology solutions. MRI-guided Radiation Therapy Systems represent a significant advancement in oncology, merging high-resolution magnetic resonance imaging (MRI) with radiation delivery technology to improve the precision and efficacy of cancer treatment. These systems combine an MRI scanner with a linear accelerator (LINAC), allowing clinicians to visualize soft tissues in real time while ... Continue reading →

According to FutureWise analysis, the Mucormycosis market in 2026 is US$0.54 billion, and is expected to reach US$0.81 billion by 2036 at a CAGR of 4.14%.  The Mucormycosis market is experiencing growth due to an increased incidence of risk factors, such as uncontrolled diabetes, immunocompromised conditions, and a rising number of organ transplant recipients who require immunosuppressive therapy. The COVID-19 pandemic has underscored the vulnerability of certain patient populations to opportunistic fungal infections, leading to greater awareness and improved diagnostic capabilities. Antifungal agents, including formulations of amphotericin B, posaconazole, and isavuconazole, remain the cornerstone of treatment for this condition. Ongoing research is focused on developing novel therapeutic approaches. The high mortality rate associated with mucormycosis, along with the necessity for aggressive early intervention, is driving demand for effective treatment options and diagnostic ... Continue reading →

According to FutureWise analysis the market for mri-safe neurostimulation systems in 2026 is US$ 0.45 billion, and is expected to reach US$ 1.37 billion by 2036 at a CAGR of 11.78%. MRI-safe neurostimulation systems enable patients with implanted devices, like spinal cord or deep brain stimulators, to safely undergo MRI scans without risk of device malfunction. These systems use specialized materials and shielding to prevent heating, movement, or interference. The increasing adoption of implantable neuromodulation therapies and the demand for diagnostic imaging are driving market growth. MRI-safe neurostimulation systems represent a significant advancement in the field of implantable medical devices, specifically designed to provide therapeutic electrical stimulation to targeted nerves or regions of the brain while ensuring safety during magnetic resonance imaging (MRI) procedures. These devices are widely utilized in the management of chronic pain, Parkinson’s disease, ... Continue reading →

According to FutureWise analysis the market for mRNA sequencing in 2026 is US$ 3.81 billion, and is expected to reach US$ 8.39 billion by 2036 at a CAGR of 8.21%. mRNA sequencing, or RNA sequencing (RNA-Seq), is a crucial technology for analyzing gene expression by sequencing messenger RNA in cells or tissues. It helps identify differentially expressed genes, detect novel transcripts, and understand disease mechanisms. Its increasing use in oncology, precision medicine, drug discovery, and biomarker development is driving significant market growth. mRNA sequencing, commonly referred to as RNA sequencing (RNA-Seq), is a cutting-edge technique in molecular biology that enables researchers to conduct a thorough analysis of the transcriptome. This includes all the messenger RNA (mRNA) molecules found in a cell or tissue at a particular moment in time. This method enables researchers to explore gene expression patterns and understand cellular functions and biological responses under ... Continue reading →

According to FutureWise analysis the market for Mucosal Atomization Devices in 2026 is US$ 0.62 billion, and is expected to reach US$ 1.25 billion by 2036 at a CAGR of 7.26%. Mucosal atomization devices are specialized drug delivery systems that administer medications as a fine mist to mucosal surfaces, allowing for quick absorption into the bloodstream. They are commonly used in emergency medicine, pain management, vaccination, and pediatric care due to their non-invasive design and ease of use. The growing preference for needle-free delivery and demand for rapid therapeutic solutions are driving steady market growth. Mucosal Atomization Devices (MADs) represent a significant advancement in drug delivery technology, offering a needle-free method for administering medications through mucosal surfaces such as the nose, mouth, or buccal cavity. These devices work by transforming liquid medications into a fine mist, which allows for rapid absorption through the richly vascularized ... Continue reading →

According to FutureWise analysis the Mucous Membrane Pemphigoid Treatment Market in 2026 is US$ 6.40 billion, and is expected to reach US$ 10.17 billion by 2036 at a CAGR of 4.74%. Market growth is driven by rising diagnosis rates of rare autoimmune blistering disorders and better access to therapies. Advances in targeted treatments, such as corticosteroids and monoclonal antibodies, are improving patient outcomes. Increased awareness among healthcare professionals and ongoing research are expected to support further market expansion. Mucous Membrane Pemphigoid (MMP) is a rare and chronic autoimmune blistering disorder that primarily affects the mucous membranes, including those of the mouth, eyes, nose, throat, and genital areas. This condition arises when the immune system mistakenly targets proteins found within the basement membrane of these tissues, leading to the formation of painful blisters, erosions, inflammation, and potential scarring. If MMP is left untreated, it can lead ... Continue reading →

According to FutureWise analysis the market for Mucus Clearance Devices in 2026 is US$ 0.79 billion, and is expected to reach US$ 1.43 billion by 2036 at a CAGR of 6.11%. Market expansion is fueled by the growing prevalence of chronic respiratory conditions like COPD and cystic fibrosis. The rise of non-invasive airway clearance therapies and portable homecare devices enhances patient convenience and adherence. Technological advancements in OPEP and high-frequency chest wall oscillation systems also support market growth. Mucus clearance devices are essential medical instruments designed to assist patients in removing excess mucus from their airways. This functionality not only enhances breathing but also lowers the likelihood of respiratory complications. These devices are particularly important in managing chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, asthma, and various neuromuscular disorders. In these ... Continue reading →

According to FutureWise analysis the market for Multiple Myeloma Diagnostics in 2026 is US$ 15.07 billion, and is expected to reach US$ 33.19 billion by 2036 at a CAGR of 8.22%. Market growth is driven by the rising incidence of hematologic malignancies and the adoption of advanced diagnostic technologies such as flow cytometry and next-generation sequencing. Increased awareness, early screening, personalized treatments, and advancements in biomarker discovery also enhance diagnostic accuracy and patient outcomes. Multiple myeloma diagnostics encompass a variety of laboratory tests, imaging techniques, and molecular tools used to identify, confirm, and monitor multiple myeloma, a type of blood cancer originating in plasma cells within the bone marrow. Plasma cells are crucial to the immune system, as they are responsible for producing antibodies. However, in multiple myeloma, these cells multiply uncontrollably and produce abnormal proteins, resulting in complications such as bone ... Continue reading →